Introduction
Central airway obstruction (CAO) is associated with high morbidity and mortality. Endobronchial stenting is a treatment for CAO but there is limited evidence on its impact.
 
Aims
To evaluate stenting practices and outcomes in CAO at a tertiary centre serving four additional secondary care trusts.
 
Methods
Endobronchial stent insertions between January 2012 and February 2023 were identified from theatre records. Data collected included diagnosis, complications and outcomes. Indications, referral pattern and outcomes were assessed.
 
Results
Of 49 patients who underwent stenting, 25(51%) were female. The median[interquartile range] age was 66[58-71] years. Primary lung cancer accounted for 29(59%) cases, with NSCLC-squamous cell carcinoma the commonest. Median time from procedure to death was 104[44-365] days and lower in malignant disease, [72[39-275]days versus 624.5[183.5-899.75]days in benign disease (p=0.03)].
 
Source of referral was from the tertiary centre in 32/49(65%) cases and only these increased over time. No difference in complication rates were seen between source of referral (p=0.29). Survival post procedure did not change over time (p=0.26). Complications occurred in 16(33%) procedures. In malignant disease, complications were associated with reduced post procedure survival (median 36.5[8.5-65] versus 159[58-365]) (p<0.01).
 
Conclusions
Endobronchial stenting has increased over time with no change in outcomes. More work to understand referral practices and patient selection remains vital for managing patients with CAO.